Stockscreener 앱 받기
25.10
1.50%
0.37
시장 영업 전:
25.23
0.13
+0.52%
전일 마감가:
$24.73
열려 있는:
$24.75
하루 거래량:
18.68M
Relative Volume:
1.97
시가총액:
$9.77B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-2.8751
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
-6.66%
1개월 성능:
-26.50%
6개월 성능:
-19.27%
1년 성능:
-68.22%
1일 변동 폭
$24.28
$25.64
1주일 범위
$24.28
$27.80
52주 변동 폭
$23.15
$80.56
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.10 | 9.62B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Hsbc Holdings PLC Has $17.91 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Wellington Management Group LLP Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
What data driven models say about Moderna Inc.’s futureWeekly Risk Summary & AI Enhanced Trading Signals - Newser
Can Moderna Inc. rally from current levelsInflation Watch & Expert Approved Trade Ideas - Newser
Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine - Insider Monkey
Earnings visualization tools for Moderna Inc.Weekly Profit Analysis & Reliable Entry Point Trade Alerts - Newser
Credit Agricole S A Decreases Position in Moderna, Inc. $MRNA - MarketBeat
Candriam S.C.A. Decreases Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Aberdeen Group plc - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Russell Investments Group Ltd. - MarketBeat
Volume spikes in Moderna Inc. stock – what they meanMarket Activity Summary & Fast Moving Market Watchlists - Newser
Jump Financial LLC Has $25.58 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Comparing Moderna Inc. in custom built stock radarsEarnings Overview Summary & Community Consensus Picks - Newser
Korea Investment CORP Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Cresset Asset Management LLC Buys Shares of 18,420 Moderna, Inc. $MRNA - MarketBeat
FDA approves COVID-19 vaccines only for ‘high risk’ people - Yahoo News Australia
Which COVID-19 vaccines are FDA approved in US? - Reuters
FDA Curbs Covid Shot Access as RFK Jr. Takes Tougher Stance - Bloomberg.com
Moderna to Present at Upcoming Conferences in September 2025 - Canton Repository
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines - Benzinga
FDA approves updated COVID boosters, but narrows use - BioPharma Dive
Why Moderna (MRNA) Stock Is Up Today - TradingView
Moderna Receives US FDA Approval for Updated COVID-19 Vaccines Targeting the LP.8.1 Variant - MarketScreener
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Joplin Globe
Latest COVID Defense: Moderna's New LP.8.1 Vaccines Cover 4M Annual Cases, FDA Gives Green Light - Stock Titan
FDA approves updated Covid vaccines, including mRNA shots from Pfizer, Moderna - Endpoints News
FDA authorizes updated Covid-19 shots, but with restrictions - Seeking Alpha
F.D.A. Approves Covid Shots With New Restrictions - The New York Times
Moderna (NASDAQ:MRNA) Stock Price Down 5.2% Following Analyst Downgrade - MarketBeat
Moderna Challenged on Bid to Shift Covid-Shot Patent Costs to US - Bloomberg Law News
Stock Analysis | Moderna OutlookA Deep Dive Into Mixed Signals and Key Catalysts - AInvest
Groupe la Francaise Has $284,000 Stake in Moderna, Inc. $MRNA - MarketBeat
Northern Trust Corp Buys 160,572 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Sells 183,308 Shares of Moderna, Inc. $MRNA - MarketBeat
Developing predictive dashboards with Moderna Inc. dataMarket Volume Report & AI Optimized Trading Strategy Guides - Newser
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Corpus Christi Caller-Times
Short interest data insights for Moderna Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Will breakout in Moderna Inc. lead to full recovery2025 Support & Resistance & Growth Focused Investment Plans - Newser
Moderna Inc. stock retracement – recovery analysis2025 Trading Recap & Intraday High Probability Setup Alerts - Newser
Moderna, Inc. shares fall 2.37% intraday amid political uncertainty and Fed independence concerns. - AInvest
Market reaction to Moderna Inc.’s recent newsDollar Strength & Long-Term Growth Portfolio Plans - Newser
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
Using RSI to spot recovery in Moderna Inc.July 2025 Opening Moves & Pattern Based Trade Signal System - Newser
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):